Dynavax Tech (DVAX)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and inte...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 15.500
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 15.720
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Dynavax Tech Analyst Rating
View moreForecast & Rating
Dec 24, 2025Price forecast
$20.5032.26%
Forecast & RatingHold
3analysts
- Strong buy33.33%
- Buy0.00%
- Hold33.33%
- Sell33.33%
- Strong sell0.00%
News
- Global Report · 2 days ago, 10:12 AM
The Quiet Consolidation: What Unclassified Mergers Tell Us About the 2026 Market
- TradingView · May 19 at 09:23 PM
Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027
- Tip Ranks · Apr 7 at 09:33 AM
Dynavox Group Highlights Mission in 2025 Annual and Sustainability Report
- StockTitan · Mar 31 at 03:10 PM
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update | RVXCF Stock News
- Tip Ranks · Mar 20 at 07:36 AM
Dynavox Group CFO to Step Down in Planned Transition by January 2027
- Tip Ranks · Mar 17 at 09:44 PM
BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order
